LUCD · Lucid Diagnostics Inc.

The price reported in Column 4 is a weighted average purchase price. These shares were purchased in multiple transactions at prices ranging from $0.9375 to $1.0200, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth herein.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed

The option was granted pursuant to the issuer's Amended and Restated 2018 Long-Term Incentive Equity Plan. One third of the option vests on June 30, 2026 and the balance vests in eight equal quarterly installments, starting September 30, 2026 and ending on June 30, 2028.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.0085 to $1.0286. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (1) to this Form 4.

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.305 to $1.32, inclusive.

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.315 to $1.32, inclusive.

The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $1.265 to $1.30. inclusive. The reporting person undertakes to provide to Lucid Diagnostics Inc., any security holder of Lucid Diagnostics Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the ranges set forth in footnotes (1), (2) and (3) to this Form4.

Includes 52,718 shares of Lucid common stock distributed on a pro rata basis to the reporting person by a limited partnership of which the reporting person is a limited partner.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. McGrath, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 142,227 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Dr. Aklog, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 6,763 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. O'Neil, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2028. Such restricted stock is subject to forfeiture if the requisite service period is not completed

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2026. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 6,763 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. O'Neil, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2026. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 19,169 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Mr. McGrath, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2026. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2026. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

Includes 142,227 shares of Lucid common stock distributed by PAVmed on February 15, 2024 to Dr. Aklog, representing his share of the shares of Lucid common stock distributed by PAVmed to its shareholders on a pro rata basis on such date.

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

One third of the option vests on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025.

Distribution by the Reporting Person as a pro rata dividend to the owners of common and preferred stock of the Reporting Person.

Issuance of common stock by the Issuer to the Reporting Person in satisfaction of a commercial agreement.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

Each sale was in connection with the Reporting Person's estimated income tax withholdings related to vested restricted stock.

Represents shares the Reporting Person received as a restricted stock grant under the Issuer's 2018 Equity Plan. Such grant was 169,320 shares of common stock, 50% of which vested September 20, 2022 and 50% of which vested September 20, 2023.

The reported sales of shares occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 16, 2023.

One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023.

One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023.

One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023.

One third of the option vests on March 31, 2023; the balance vests in eight equal quarterly installments, starting June 30, 2023.